John Fritz, DO
Family Medicine · Jersey City, NJNPI 1316032394
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,430 of the $21,523 with a category attached, or 67.0%. 26 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 46.5% of the total. Reporting peaked in 2019 at $18,855 and has fallen 99.8% since, to $32 in 2025. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $73.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$10K
- AbbVie$5K
- Teva Pharmaceuticals USA, Inc.$3K
- LEO Pharma Inc.$1K
- Monteris Medical Corporation$385
- Medtronic$259
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$14,43067%
- Travel & lodging$2,05210%
- Food & beverage$5,02923%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 35 | $10,005 |
| AbbVie | 49 | $5,283 |
| Teva Pharmaceuticals USA, Inc. | 17 | $2,915 |
| LEO Pharma Inc. | 122 | $1,463 |
| Monteris Medical Corporation | 5 | $385 |
| Medtronic | 3 | $259 |
| Romark Laboratories, LC | 2 | $225 |
| Sanofi | 1 | $185 |
| Boehringer Ingelheim | 13 | $175 |
| Lilly USA, LLC | 11 | $147 |
| Merck | 10 | $138 |
| Mannkind Corporation | 4 | $59 |
| AstraZeneca | 3 | $35 |
| Radius Health, Inc. | 2 | $28 |
| Aytu Biopharma, Inc. | 2 | $27 |
| Valeritas, Inc. | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Scilex Pharmaceuticals Inc. | 2 | $26 |
| Glycomark, Inc. | 1 | $22 |
| Promius Pharma LLC | 1 | $15 |
| Amgen | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$5,382
- TOUJEO$4,395
- Creon$3,135
- AJOVY$2,729
- Alinia$674
- Neuroblate$343
- VISUALASE$242
How this compares
$21,523 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 134 | $353,798 |
| EnstilarCalcipotriene/Betamethasone | 92 | $270,968 |
| Relafen DsNabumetone | 21 | $188,280 |
| JanuviaSitagliptin Phosphate | 174 | $147,817 |
| Bydureon BciseExenatide Microspheres | 161 | $135,587 |
| Chlorpromazine Hcl | 162 | $112,664 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 191 | $106,103 |
| TrulicityDulaglutide | 76 | $102,085 |
| Spiriva HandihalerTiotropium Bromide | 157 | $98,265 |
| TradjentaLinagliptin | 128 | $93,295 |
| XeljanzTofacitinib Citrate | 15 | $87,204 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 111 | $72,707 |
| RestasisCyclosporine | 70 | $55,032 |
| VascepaIcosapent Ethyl | 70 | $44,269 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 283 | $40,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess | $5,283 | $439,260261 claims |
| LEO Pharma Inc.Enstilar | $1,463 | $270,96892 claims |
| Boehringer IngelheimCombivent Respimat, Tradjenta, Spiriva Respimat, Jentadueto | $175 | $262,229427 claims |
| MerckJanuvia, Janumet | $138 | $179,233205 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $134,968104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $10,005 | $33,33228 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $2,915 | $17,15751 claims |
| AstraZenecaFarxiga | $35 | $16,78018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Jersey City
- Sally MravcakJersey City$64K
- Rupal BhingradiaJersey City$13K
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.